Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
In recent years, the occurrence of a wide variety of drug-resistant diseases has led to an increase in interest in alternate therapies. Peptide-based drugs as an alternate therapy hold researchers' attention in various therapeutic fields such as neurology, dermatology, oncology, metabolic diseases, etc. Previously, they had been overlooked by pharmaceutical companies due to certain limitations such as proteolytic degradation, poor membrane permeability, low oral bioavailability, shorter half-life, and poor target specificity. Over the last two decades, these limitations have been countered by introducing various modification strategies such as backbone and side-chain modifications, amino acid substitution, etc. which improve their functionality. This has led to a substantial interest of researchers and pharmaceutical companies, moving the next generation of these therapeutics from fundamental research to the market. Various chemical and computational approaches are aiding the production of more stable and long-lasting peptides guiding the formulation of novel and advanced therapeutic agents. However, there is not a single article that talks about various peptide design approaches i.e., in-silico and in-vitro along with their applications and strategies to improve their efficacy. In this review, we try to bring different aspects of peptide-based therapeutics under one article with a clear focus to cover the missing links in the literature. This review draws emphasis on various in-silico approaches and modification-based peptide design strategies. It also highlights the recent progress made in peptide delivery methods important for their enhanced clinical efficacy. The article would provide a bird's-eye view to researchers aiming to develop peptides with therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 5×
“This modification protects the peptides from proteolytic enzymes by increasing the molecular mass of peptides and improving their pharmacokinetic profiles (Harris and Chess 2003; Suk et al.”
BackgroundInfluentialHopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 2×
“Small molecules target only 2–5% of the human genome but peptides are more selective for specific protein targets (Cirillo et al. 2011; Hopkins and Groom 2002; Lau and Dunn 2018; Rask-Andersen et al. 2014; Vargason et al. 2021).”
BackgroundAdrenomedullin: A Novel Hypotensive Peptide Isolated from Human Pheochromocytoma
Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., & Eto, T. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1451 · Cited by 2,192
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879 · cited 10×
“• Peptides in Clinical Trials Phases Lau and Dunn reported a series of peptides that entered human clinical trials including many peptides in active clinical development (Lau and Dunn 2018).”
BackgroundInfluentialThe evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Contemporary strategies for peptide macrocyclization
White, C. J., & Yudin, A. K. (2011) · Nature Chemistry · doi:10.1038/nchem.1062 · Cited by 1,088
Glutamine Metabolism in Cancer: Understanding the Heterogeneity
Cluntun, A. A., Lukey, M. J., Cerione, R. A., & Locasale, J. W. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.01.005 · Cited by 796
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Cited by
Azadi, S., Yazdanpanah, M. A., Afshari, A., Alahdad, N., Chegeni, S., Angaji, A., Rezayat, S. M., & Tavakol, S. (2024) · Journal of Tissue Engineering · doi:10.1177/20417314241303818 · Cited by 24
Murail, S., Sawmynaden, J., Zemirli, A., Jusot, M., Pietrucci, F., Chomilier, J., Tufféry, P., & Stratmann, D. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c01123 · Cited by 6
Metadata
- Authors
- Barman, P., Joshi, S., Sharma, S., Preet, S., Sharma, S., & Saini, A.
- Venue
- International Journal of Peptide Research and Therapeutics
- Published
- 2023-05-24
- Volume
- 29
- Issue
- 4
- Pages
- 61-61
- ISSN
- 1573-3149 (ISSN-L)
- 1573-3904
- OpenAlex
- W4377942021
- Cited by
- 116
- References
- 19
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics. https://app.cochat.ai/papers/10.1007/s10989-023-10524-3
- The paper
- Barman, P., Joshi, S., Sharma, S., Preet, S., Sharma, S., & Saini, A. (2023). Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics. International Journal of Peptide Research and Therapeutics. https://doi.org/10.1007/s10989-023-10524-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.